The New York Entrepreneur

Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda

Read Time:7 Second

The drugmaker raised its full-year sales forecast to $63.4 billion to $64.4 billion on increased demand for key products, particularly oncology treatments.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says
Next post Pfizer’s stock pops after earnings beat as company raises guidance and unveils cost cuts